Lung cancer is one of the malignant tumors with the highest morbidity and mortality rates worldwide, seriously threatening human health. Non-small cell lung cancer (NSCLC) accounts for more than 85% of all lung cancer cases. STMN1 is a microtubule depolymerizing protein widely present in the cytoplasm and its expression level is associated with the prognosis of NSCLC patients. Through meta-analysis, this study aimed to investigate the predictive value of the expression level of STMN1 for the prognosis of lung cancer and screen for tumor markers with high sensitivity and specificity to optimize the whole-process management of lung cancer patients.

Objective: The incidence of early-onset colorectal cancer (EOCRC) is increasing globally; however, the molecular characteristics and prognosis of sporadic EOCRC are unclear. In this systematic review and meta-analysis, we aimed to investigate the incidence of gene mutations and their association with cancer survival in sporadic EOCRC, focusing on six common gene mutations (TP53, BRAF, KRAS, NRAS, PTEN, and APC). Methods: Ovid Embase and Ovid Medline electronic databases were searched for studies involving patients with sporadic EOCRC (i.e., diagnosed with colorectal cancer before the age of 50 years and with no evidence of hereditary syndromes predisposing to colorectal cancer). The included articles were evaluated using quality assessment tools. Meta-analysis was performed using random-effects and fixed-effects models. Cochran's Q statistic and the I2 index were used to assess heterogeneity. The incidence of the six common gene mutations listed above in sporadic EOCRC and their association with cancer survival were evaluated. Results: (1) Incidence of specific gene mutations in sporadic EOCRC. A total of 34 articles were included in this meta-analysis. The incidence of APC gene mutation was 36% (from 13 articles, 95%CI: 19%-55%, P=0.043); of KRAS gene mutation 30% (from 26 articles, 95%CI: 24%-35%, P=0.190); of BRAF gene mutation 7% (from 18 articles, 95%CI: 5%-11%, P=0.422); of NRAS gene mutation 4% (from five articles, 95%CI: 3%-5%, P=0.586); of PTEN gene mutation 6% (from six articles, 95%CI: 4%-10%, P=0.968); and of TP53 gene mutation 59% (from 13 articles, 95%CI: 49%-68%, P=0.164). (2) Association between gene mutations and survival in sporadic EOCRC. A total of six articles were included in this meta-analysis. Compared with wild-type BRAF, mutant BRAF was significantly associated with increased overall mortality risk in patients with EOCRC (pooled HR=2.85, 95%CI: 1.45-5.60, P=0.002). Subgroup analysis showed that the incidence of BRAF gene mutation was higher in Eastern than in Western countries, whereas the incidence of TP53, KRAS, NRAS, and APC gene mutations was lower. There was no significant difference in the incidence of PTEN gene mutation between different regions. Conclusion: Compared with colorectal cancer occurring in the general population, the incidence of APC and KRAS mutations is lower in EOCRC, whereas the incidence of TP53 mutation remains consistent. BRAF mutation is associated with increased overall mortality risk in patients with EOCRC.

Lung cancer is the most common malignant tumor in clinic. The prognosis of advanced patients is poor, and the 5-year survival rate is low. Therefore, early diagnosis becomes the key to improve the prognosis of patients. In recent years, with the development of molecular biology technology, aberrant modification of some driver genes, such as methylation, has become an important method for early diagnosis of lung cancer. The purpose of the present work was to quantitatively evaluate the diagnostic value of abnormal hypermethylation in short state homeobox 2 (SHOX2) promoter region in lung cancer by evidence-based medicine.

Objective: Using Meta-analysis to evaluate the association between Pin1 gene polymorphism at -842 loci and cancer susceptibility. Methods: Pin1, polymorphism, tumor, variant and cancer as key words were used to systematically search for the case-control research on the association between the -842G/C polymorphisms of Pin1 and cancer susceptibility through China National Knowledge Infrastructure (CNKI), Wanfang Data, Embase and PubMed. The time of literatures was up to April 2(nd), 2019. Heterogeneity test, combined risk of cancer with the -842 C allele of Pin1, publication bias test and sensitivity analysis were performed by using Stata 12.0 software. Results: A total of 144 articles were retrieved. According to the inclusion criteria, a total of 11 articles were included (2 Chinese documents and 9 English documents). There were 5 667 cases and 6 120 controls in eligible articles. The heterozygous model showed that Pin1 (-842G/C) polymorphism was associated with cancer susceptibility, and the pooled OR (95%CI) value was 0.78 (0.61, 0.99). Subgroup analysis by cancer type suggested that the Pin1 (-842G/C) polymorphism could significantly decrease the incidence of breast cancer and lung cancer under the heterozygous model (GC vs GG), dominant model (GC+CC vs GG) and allele model (C vs G). The pooled OR (95%CI) values were 0.73 (0.58, 0.92), 0.71 (0.57, 0.89), and 0.73 (0.60, 0.89) in breast cancer and 0.64 (0.52, 0.78), 0.64 (0.53, 0.78), and 0.67 (0.55, 0.80) in lung cancer. The variant -842 C allele could significantly increase the risk of nasopharyngeal carcinoma under the homozygote model (CC vs GG) and recessive model (CC vs GG+GC). The pooled OR (95%CI) values were 2.22 (1.03-4.75) and 2.47 (1.16-5.26). No significant association was observed in squamous cell carcinoma. Conclusion: This Meta-analysis demonstrated that Pin1gene polymorphism at -842 was associated with cancer susceptibility.

Objective To investigate the expression and clinical significance of whey acidic protein (WAP) 4-disulfide core domain 2 (WFDC2) in ovarian cancer. Methods The expression of WFDC2 gene in normal human tissues, ovarian cancer tissues and ovarian cancer cell lines and the correlation with the prognosis survival in patients with ovarian cancer were analyzed using the BioGPS database, Oncomine database, Cancer Cell Encyclopedia (CCLE) and Kaplan-Meier Plotter databases. Results BioGPS database analysis showed that the expression of WFDC2 was not found in normal ovarian tissues. Four hundred and seventeen samples were searched from Oncomine database, and the different expression of WFDC2 in 34 studies were statistically significant, which included the WFDC2 expression increasing in 19 studies, and WFDC2 expression decreasing in 15 studies. Meta-analysis of 7 studies meeting the setting conditions showed that the expression level of WFDC2 was high in ovarian cancer tissues. CCLE analysis showed that the expression level of WFDC2 was also high in ovarian cancer cell lines; Kaplan-Meier Plotter database results showed the overall survival time of patients with ovarian cancer in the high WFDC2 expression group was significantly longer than that in the low WFDC2 expression group. Conclusion The expression of WFDC2 in ovarian cancer tissues is high, and which is significantly associated with the prognosis survival in patients with ovarian cancer.

Molecular target therapy is one of the most popular field of non-small cell lung cancer (NSCLC) treatmnet. Epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearragement are the most important two oncogenic drivers in NSCLC, early studies suggested that EGFR mutations and ALK rearrangements are mutually exclusive, but isolated cases or small sample research with concomitant EGFR and ALK alterations have been constantly reported. The co-occurrence of EGFR mutations and anaplastic lymphoma kinase (ALK) rearrangements constitutes a rare molecular, the frequency of EGFR/ALK co-alterations was about 1%, however, little has been known about clinicopathologic feature and treatment. This review summarized published case report, EGFR and ALK alterations are common in female, Asian origin, never smoker, IV stage, and denocarcinomas. First-line treatment can choose EGFR or ALK tyrosine kinase inhibitors (TKIs). However, studies about the origin and resistance mechanism in EGFR/ALK co-alterations are little, require more experimental and clinical research.
.

To conduct a comprehensive quantitative analysis about the association between genetic polymorphisms of CYP 2E1 and susceptibility to Chinese gastric cancer in order to offer evidence-based evidence for the etiology of gastric cancer.

Objective: To investigate the association between miR-146a single nucleotide polymorphism and genetic susceptibility to hepatocellular carcinoma (HCC). Methods: PubMed, Web of Science, Cochrane Library, Wanfang Data, and Google Scholar were searched for case-control studies on the association between miR-146a single nucleotide polymorphism and genetic susceptibility to HCC published up to October, 2016 in Chinese or English. The Q-statistics test was used to evaluate the heterogeneity of these articles. Results: A total of 18 articles with 5 610 cases and 7 531 controls were included for the meta-analysis. There was no significant association between miR-146a single nucleotide polymorphism and genetic susceptibility to HCC. The odds ratio (OR), 95% confidence interval (95% CI), and P values for the five genetic models were as follows: the allele model C/G (OR = 0.99, 95% CI 0.88-1.06, P = 0.440); the heterozygous model CG/GG (OR = 0.99, 95% CI 0.90-1.10, P = 0.898); the homozygous model CC/GG (OR = 0.91, 95% CI 0.75-1.10, P = 0.314); the dominant model CC+CG/GG (OR = 0.97, 95% CI 0.79-1.19, P = 0.759); the recessive model CG+GG/CC (OR = 1.05, 95% CI 0.94-1.18, P = 0.405). A subgroup analysis of race, source of control population, and Hardy-Weinberg equilibrium were performed in these five genetic models, and miR-146a single nucleotide polymorphism increased the susceptibility to HCC only in the control population-based subgroups of the recessive model CG+GG/CC (OR = 1.20, 95% CI 1.02-1.40, P = 0.024). There was no association between miR-146a rs2910164 polymorphism and susceptibility to HCC in all the other subgroups. A stratified analysis of HBV infection revealed that miR-146a rs2910164 polymorphism increased the risk of HBV-positive HCC (OR = 1.26, 95% CI 1.10-1.49, P = 0.001). Conclusion: There is no significant association between miR-146a rs2910164 polymorphism and the risk of HCC, but miR-146a rs2910164 polymorphism may increase the risk of HBV-positive HCC.

To analyze the relationship between GST polymorphism and childhood acute lymphoblastic leukemia(ALL) risk.

To systematically review the prognostic value regarding the expression of long non-coding RNA (lncRNA) Hox transcript antisense intergenic RNA (HOTAIR) in patients with cancer. 
 Methods: Databases including The Cochrane Library, EMBASE, MEDLINE, and PubMed were searched to collect English literature on the correlation between lncRNA HOTAIR expression and overall survival in tumors. The retrieval time was from inception to September 2015. After data were extracted, a Meta-analysis was performed using RevMan 5.3 software.
 Results: A total of 17 studies were included, which was involved in 1 639 patients. The Meta-analysis showed that high expression of HOTAIR could predict poor overall survival in cancer (HR: 2.39, 95% CI 2.01-2.86, P<0.001). High expression of HOTAIR could also predict poor overall survival both in digestive tumor (HR: 2.51, 95% CI 2.02-3.11, P<0.001) and non-digestive tumor (HR: 2.17, 95% CI 1.59-2.98, P<0.001). Moreover, overexpression of HOTAIR was found to be significantly associated with recurrence-free survival.
 Conclusion: The overexpression of lncRNA HOTAIR might be associated with poor prognosis in patients with cancer.

The combination therapy of chemotherapy and epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) has attracted the attention of more and more investigators. The aim of this meta-analysis is to evaluate the clinical efficacy and safety of intercalated combination of chemotherapy and EGFR- TKIs versus chemotherapy alone in the first-line therapy of advanced non-small cell lung cancer (NSCLC).

To systematically review the potential value of long noncoding RNA (lncRNA) metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) as a potential novel prognostic biomarker in cancers.
 Methods: Databases including Cochrane Library, Medline, Embase, PubMed databases were searched for all English studies, which explored the correlation between lncRNA MALAT1 expression and overall survival in tumors. The retrieval time was from inception to August 1, 2015. Two reviewers independently screened literature according to the inclusion and exclusion criteria, extracted data, and assessed methodological quality. Then, Meta-analysis was performed using RevMan 5.3 software.
 Results: Ten studies covered a total of 1 016 patients. Meta-analysis showed that high expression of MALAT1 was significantly correlated to poor overall survival (OS) in patients with tumor (HR= 2.08, 95% CI 1.74 to 2.48, P<0.001). 
 Conclusion: LncRNA MALAT1 might be a potential novel prognostic biomarker in tumor.

Objective To investigate the potential association of cytotoxic T lymphocyte associated protein 4 (CTLA4) polymorphisms with non-Hodgkin's lymphoma (NHL) risk. Methods Two reviewers independently searched the PubMed, MEDLINE, China National Knowledge Infrastructure (CNKI), Chinese WanFang databases and Database of Chinese Scientific and Technical Periodicals (VIP) for relevant studies from January 1, 1990 to May 25, 2016. Odds ratios (OR) with 95% confidence intervals (CI) for CTLA4 polymorphism and HNL risk were used to evaluate the strength of association. Meta-analysis was performed using SATA (v12.0) software. Results A total of 6 case-control studies concerning the CTLA4 +49A/G, -318T/C, and CT60A/G polymorphisms were included in the meta-analysis. The polymorphisms of the three alleles were not associated with genetic susceptibility to NHL (PZ>0.05 or 95%CI contains 1). In the subgroup analysis of CTLA4 +49A/G gene polymorphism, we found that AA was a risk factor for mixed type lymphoma (AA vs GG: OR=4.181, 95%CI: 1.362-12.833; AA+AG vs GG: OR=3.217, 95%CI: 1.055-9.810; AA vs AG+GG: OR=2.827, 95%CI: 1.345-5.940), but was a protect factor for B cell lymphoma (AA vs GG: OR=0.465, 95%CI: 0.251-0.863; AA vs AG+GG: OR=0.534, 95%CI: 0.362-0.788); AA was a risk factor in Italians (AA vs GG: OR=4.181, 95%CI: 1.362-12.833; AA+AG vs GG: OR=3.217, 95%CI: 1.055-9.810; AA vs AG+GG: OR=2.827, 95%CI: 1.345-5.940), but was a protect factor in Chinese (AA vs GG: OR=0.643, 95%CI: 0.417-0.992; AA vs AG+GG, OR=0.601, 95%CI: 0.395-0.913). Conclusion This meta-analysis suggests that the polymorphisms of the three alleles are not associated with genetic susceptibility to NHL.

To investigate the relationship between microRNA-149 (rs2292832), microRNA-499 (rs2292832) polymorphism and hepatocellular carcinoma susceptibility by meta-analysis.

The fusion between echinoderm microtubule-associated protein 4 (EML4) and anaplastic lymphatic tumor kinase (ALK) rearrangement is present in approximately 5% of non-small cell lung cancer (NSCLC) patients. It has been regarded as another new target gene after epidermal growth factor receptor (EGFR) and K-ras. Figures showed that the disease control rate could reach up to 80% in NSCLC patients with EML4-ALK fusion gene after treated with ALK inhibitors. Thus, exploring an accurate and rapid detecting method is the key in screening NSCLC patients with EML4-ALK expressions. The aim of this study is to analyze the specificity and sensitivity of IHC in detecting EML4-ALK fusion mutations. To evaluate the accuracy and clinical value of this method, and then provide basis for individual molecular therapy of NSCLC patients.

To explore the association between CYP1A1*2A polymorphism and susceptibility to childhood acute lymphoblastic leukemia (ALL) through a Meta analysis.

The CpG island aberrant promoter methylation in the tumor suppressor gene region plays an important role in the process of tumorigenesis. Relevant evidence shows that the promoter methylation of RAS association domain family 1A (RASSF1A) gene, a tumor suppressor gene, has a close relationship with non-small cell lung cancer (NSCLC) development; therefore, RASSF1A may be a potential NSCLC biomarker. This paper discussed and summarized the relationship between RASSF1A gene promoter methylation frequency and NSCLC through meta-analysis.

To evaluate the effects of DNMT3A gene mutation on prognosis of patients with acute myeloid leukemia (AML) by a meta-analysis.

Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) has been used for the first-line treatment of non-small cell lung cancer (NSCLC) and has shown good clinical effects. However, some patients fail to benefit from this treatment. The aim of this study is to analyze whether or not clinical-selected patients (Asian, adenocarcinoma histology, non-smoking) and EGFR mutation-selected patients benefit from EGFR-TKIs or chemotherapy. Our results could be used as basis to guide clinical therapy.

To analyze and explore the association between the 1607(1G/2G) single nucleotide polymorphism (SNP) in promoter of matrix metalloproteinase-1 (MMP-1) gene and susceptibility of head and neck cancer (HNC) by Meta-analysis.